Bharat Biotech today emphatically denied any wrongdoing amid a huge controversy in Brazil over a $324 million contract for Covaxin shots, now suspended over allegations of irregularities. In a statement, Bharat Biotech said it had followed a "step-by-step" approach towards contracts and regulatory approvals with Brazil.